Drug companies are using women of colour and First Nations celebrities in weight-loss campaigns. Not everyone’s happy.
Articles on Weight loss drugs
Displaying 1 - 20 of 45 articles
GLP-1 drugs can produce major weight loss, but their wider impact will depend on affordable treatment and appropriate support.
Some research suggests between 10% and 30% of GLP-1 drug users may be considered non-responders.
Ozempic-style drugs have been flagged as possible treatments for cancer, dementia, endo, addiction and more. An expert explains what the evidence really says.
The popular new drug can bring dramatic weight loss for some patients. But for NZ, tackling a rising obesity epidemic is likely to require much broader change.
Grey-market peptides are becoming mainstream, but evidence of their effectiveness is thin or non-existent.
In a clinical trial, this small-molecule drug was found to be superior to semaglutide for lowering blood sugar.
A major study links Wegovy to a rare form of sudden vision loss, and finds men may face three times the risk of women.
GLP-1 drugs are the first medication to show promise for treating addiction to a wide range of substances.
Appetite is governed by gut hormones, not willpower. GLP-1 therapies extend natural satiety signals and expose the biology behind eating.
As GLP-1 medications surge in popularity, companies are selling tailored supplements. Science suggests most people do not need them.
Before you spend your money, here’s why you should think twice about buying a weight-loss patch.
Due to the body’s natural tendency to restore its former weight, many people regain their lost weight when they stop using GLP-1 drugs.
Firms will add new products to their ranges – but they’re unlikely to abandon reliable profits from unhealthy foods.
Australia’s regulator has issued warnings about the risk of suicidal thoughts and lower effectiveness of contraceptives in those taking Ozempic, Wegovy and Mounjaro.
The evolutionary science of weight regain unpacked.
Stigma against weight loss drugs is driving some users to take them in secret.
A new study shows drugs such as Ozempic come with a small but increased risk of a condition known as an ‘eye stroke’.
The development of new weight loss drugs is one way that patient access can be ensured in the future.
Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term habits still matter most.
Top contributors
-
Associate Professor in Pharmacy Practice, University of Bradford
-
Professor of Health Service Operations, School of Pharmacy & Medical Sciences, University of Bradford
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Research Lead/Advanced Clinical Practitioner/Senior Research Fellow, University of Bradford
-
Associate Professor of Metabolic Medicine, University of Surrey
-
Assistant Professor, Critical Disability Studies, Carleton University
-
ARC Future Fellow, School of Biomedical Sciences, The University of Queensland
-
Senior Lecturer in Food and Nutrition, Sheffield Hallam University
-
Accredited Practising Dietitian and Lecturer, Southern Cross University
-
Professor of Community Health and Wellbeing, The University of Queensland
-
Professor of Exercise Science and Interim Dean of the School of Health Sciences, College of Charleston
-
Beckwith Professor of Management Studies, Cambridge Judge Business School
-
Professor of Law, Villanova University
-
Associate Lecturer, Sydney Pharmacy School, University of Sydney
-
Senior Lecturer, University of North Carolina – Greensboro